-+ 0.00%
-+ 0.00%
-+ 0.00%

Incyte Announced Sunday, FDA Breakthrough Therapy Designation For Its Treatment For Essential Thrombocythemia With Type 1 CALR Mutation

Benzinga·12/07/2025 20:05:38
Listen to the news

The Company plans to initiate a Phase 3 program evaluating INCA033989 in essential thrombocythemia (ET) patients with all types of CALR mutations in mid-2026, following alignment with regulators Updated safety and efficacy data for INCA033989 in ET, and new data in myelofibrosis (MF), will be presented at the upcoming 2025 ASH Annual Meeting